Iovance Biotherapeutics (IOVA) Total Non-Current Liabilities (2011 - 2026)

Iovance Biotherapeutics (IOVA) has reported Total Non-Current Liabilities for 12 consecutive years, with $74.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 2.22% year-over-year to $74.5 million; the TTM figure through Mar 2026 stood at $74.5 million (down 2.22% YoY), while the FY2025 annual figure was $76.2 million, down 1.87% from the prior year.
• Total Non-Current Liabilities retreated to $74.5 million in Q1 2026 per IOVA's latest filing, from $76.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $106.6 million in Q1 2024 and bottomed at $70.6 million in Q1 2023.
• Historically, Total Non-Current Liabilities has averaged $79.6 million across 5 years, with a median of $76.2 million in 2025.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 54.66% — and 2025, when it slipped 28.53%.
• Iovance Biotherapeutics' Total Non-Current Liabilities stood at $72.9 million in 2022, then grew by 17.26% to $85.4 million in 2023, then slipped by 9.07% to $77.7 million in 2024, then declined by 1.87% to $76.2 million in 2025, then fell by 2.28% to $74.5 million in 2026.
• Business Quant data shows IOVA's Total Non-Current Liabilities at $74.5 million in Q1 2026, $76.2 million in Q4 2025, and $76.9 million in Q3 2025.